Division of Hematology and Oncology, Department of Medicine, Chang Gung Memorial Hospital, Chia-Yi, Taiwan.
Oral Oncol. 2010 May;46(5):e29-33. doi: 10.1016/j.oraloncology.2010.02.011. Epub 2010 Mar 12.
This study investigates the clinical significance of CD44 messenger RNA (mRNA) expression in the peripheral blood of patients with head and neck cancer. Real-time reverse transcriptase-polymerase chain reaction analysis was used to quantify CD44 mRNA levels in the peripheral blood of patients with locally advanced head and neck cancer. All patients were enrolled between January 2006 and December 2008 and had received chemotherapy/radiotherapy for their head and neck cancers. The pretreatment CD44 mRNA levels at a cutoff point of greater than fivefold were associated with an odds ratio of 12.5 for poor prognosis (95% CI, 3.9-40; p<0.001) and could predict poor treatment response in patients with locally advanced head and neck cancers. Larger prospective studies comparing the current assay with standardized methodologies are warranted.
本研究旨在探讨头颈部癌症患者外周血中 CD44 信使 RNA（mRNA）表达的临床意义。采用实时逆转录-聚合酶链反应分析方法对头颈部局部晚期癌症患者外周血中的 CD44 mRNA 水平进行定量。所有患者均于 2006 年 1 月至 2008 年 12 月入组，并接受化疗/放疗治疗。在截点值大于五倍的预处理 CD44 mRNA 水平与预后不良的比值比为 12.5（95%CI，3.9-40；p<0.001），并可预测局部晚期头颈部癌症患者的治疗反应不良。需要进行更大规模的前瞻性研究，将当前检测方法与标准化方法进行比较。
